| NOVAVAX INC. DL-,01 |
| USA |
| Gesundheit |
| US6700024010 / A2PKMZ |
| NVV1 (Frankfurt) / NVAX (NASDAQ) |
| FRA:NVV1, ETR:NVV1, NVV1:GR, NASDAQ:NVAX |
| - |
| https://novavax.com/ |
|
Novavax Inc. is a biotechnology company focused on developing and commercializing vaccines that address serious infectious diseases. Novavax Inc. uses a proprietary recombinant protein platform paired with its Matrix-M adjuvant technology to support ..
>Volltext.. |
| 1532.81 Mio. EUR |
| 1163.86 Mio. EUR |
| 367.62 Mio. EUR |
| -90.11 Mio. EUR |
| -220.09 Mio. EUR |
| -1.35 EUR |
| 264.14 Mio. EUR |
| 170.09 Mio. EUR |
| -32.78 Mio. EUR |
| 2.18 |
| -60.43% |
| -160.43% |
| - |
| - |
| - |
| - |
| NOVAVAX |
| 05.10.26 |
|
||||
|
||||
|
||||
|
||||
|
||||
|
||||
|
||||
|
||||
|
||||
|
||||
|
||||
|
||||
|
||||
|
||||
|
||||
|
||||
|
||||
|
||||
|
||||
|
||||
|